Volume 15, Issue 1, Pages 78-86 (January 2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Dr Hugo E R Ford, MD, Andrea Marshall, PhD, John A Bridgewater, PhD, Tobias Janowitz, PhD, Fareeda Y Coxon, MRCP, Jonathan Wadsley, FRCR, Wasat Mansoor, PhD, David Fyfe, MD, Srinivasan Madhusudan, FRCP, Prof Gary W Middleton, MD, Daniel Swinson, MD, Stephen Falk, MD, Ian Chau, MD, Prof David Cunningham, MD, Paula Kareclas, PhD, Natalie Cook, PhD, Prof Jane M Blazeby, MD, Prof Janet A Dunn, PhD The Lancet Oncology Volume 15, Issue 1, Pages 78-86 (January 2014) DOI: 10.1016/S1470-2045(13)70549-7 Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 1 Trial profile The Lancet Oncology 2014 15, 78-86DOI: (10.1016/S1470-2045(13)70549-7) Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 2 Kaplan-Meier plot of overall survival The Lancet Oncology 2014 15, 78-86DOI: (10.1016/S1470-2045(13)70549-7) Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 3 Hazard ratio plot of the treatment effect by prognostic factors for overall survival ECOG PS=Eastern Cooperative Oncology Group performance status. The Lancet Oncology 2014 15, 78-86DOI: (10.1016/S1470-2045(13)70549-7) Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 4 Health-related quality of life (HRQL) outcomes. Positive values in function scale and negative values for the symptom scale denote benefit from docetaxel compared with active symptom control. The Lancet Oncology 2014 15, 78-86DOI: (10.1016/S1470-2045(13)70549-7) Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions